The simultaneous administration of NGR-TNFα with anti-PD-1 or anti-CTLA4 and with adoptive T lymphocyte therapy increased the effectiveness of each therapy alone in prostate and melanoma models (269). The gene discussed is TNF; the disease is melanoma.